All Companies

3D Bio Corporation
De­vel­op­ing scal­able bio­print­ed car­ti­lage ther­a­peu­tics to ad­dress un­met med­i­cal needs in re­con­struc­tive and or­tho­pe­dic in­di­ca­tions with rapid reg­u­la­to­ry path­way to mar­ket. Fil­ing IND for or­phan... [more in­for­ma­tion]
4D Molecular Therapeutics
Fo­cused on the dis­cov­ery and de­vel­op­ment of pro­pri­e­tary tar­get­ed AAV gene ther­a­py vec­tors and ther­a­peu­tic prod­ucts through a ro­bust dis­cov­ery plat­form, termed Ther­a­peu­tic Vec­tor Evo­lu­tion. Th­ese... [more in­for­ma­tion]
Abide Tx
Com­pany de­vel­op­ing serine-hy­dro­lase-tar­get­ed ther­a­peu­tics to work through en­do­cann­abi­noid path­ways to ad­dress neu­ro­log­i­cal di­s­or­ders with limit­ed treat­ment op­tions. Re­port­ed pos­i­tive phase 1b re­sults... [more in­for­ma­tion]
Ablynx nv [ABLX] US$3,111 MM MCap
Nano­body plat­form with over 45 pro­pri­e­tary and part­nered pro­grams across in­di­ca­tions in­clud­ing aTTP, RSV, SLE and I-O. In Oc­to­ber 2017 re­port­ed pos­i­tive Phase III da­ta with ca­pla­cizumab for aTTP, a... [more in­for­ma­tion]
estab­lished ther­a­peu­tic anti­body com­pany vali­dat­ed through long-stand­ing part­n­er­ships with glob­al health­care lead­ers in­clud­ing Genetech, GSK, BMS, Med­im­mue, MRK, MSK, and MGH. Abpro’s... [more in­for­ma­tion]
Acceleron Pharma Inc [XLRN] US$1,947 MM MCap
De­vel­op­ing TGF-be­ta ther­a­peu­tics to treat se­ri­ous and rare dis­eas­es. Lead ther­a­peu­tic can­di­date, lus­pa­ter­cept, un­der a glob­al part­n­er­ship with Cel­gene in mul­ti­ple Ph2 and Ph3 studies for the treat­ment... [more in­for­ma­tion]
Accera, Inc.
Ad­dress­ing the metabolic de­fect fun­da­men­tal to the patho­phy­si­ol­o­gy of Alzheimers Dis­ease. Lead com­pound in­duces ke­to­sis, sup­p­ly­ing an al­ter­na­tive en­er­gy source for the pro­gres­sive de­c­line in cere­bral... [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$103 MM MCap
De­vel­op­ing DSU­VIA - HCP ad­min­is­tered sufen­tanil nan­otab with $1.1B mar­ket op­por­tu­ni­ty in ER de­part­ments, am­bu­la­to­ry surgery cen­ters, and paramedic tran­s­ports; met all end­points in 3 Ph 3 studies. [more in­for­ma­tion]
Achillion Pharmaceuticals, Inc. [ACHN] US$412 MM MCap
Pipe­line of com­ple­ment fac­tor D in­hibi­tors to treat rare dis­eas­es such as PNH and C3G. In Novem­ber 2017, re­port­ed pre­lim­i­nary proof-of-con­cept with ACH-4471 in C3G. show­ing greater than 50%... [more in­for­ma­tion]
Adamas Pharmaceuticals, Inc. [ADMS] US$870 MM MCap
Fo­cused on de­vel­op­ing drugs for chron­ic neu­ro­log­i­cal di­s­or­ders by uti­l­iz­ing time-de­pen­dent bi­ol­o­gy to match ther­a­peu­tic drug pro­files with dis­ease pat­terns to drive a more sig­ni­f­i­cant durable ef­fect. [more in­for­ma­tion]
Adaptimmune Therapeutics PLC [ADAP] US$758 MM MCap
Mul­ti­ple trials on­go­ing in both solid tu­mors and he­ma­to­log­ic can­cer types with pro­pri­e­tary T-cell en­gi­neer­ing plat­form. Da­ta read­out from NY-ESO SPEAR T-cells in NS­CLC and ovarian can­cer and da­ta from... [more in­for­ma­tion]
Affimed N.V. [AFMD] US$58 MM MCap
En­gi­neer­ing NK cell and T-cell en­gag­ing bis­pe­cif­ic anti­bodies and Tris­pe­cif­ic Abs. Lead pro­gram AFM13(CD30/CD16A)in a PhIb com­bo w/ Keytru­da for Hodgkins Lym­pho­ma. AFM13 - PhIIa monother­a­py for HL,... [more in­for­ma­tion]
Allecra Therapeutics
Ph 2 antibi­ot­ic com­pany fo­cused on ef­forts to com­bat antibi­ot­ic re­sis­tance through a dif­fer­en­ti­at­ed plat­form tar­get­ing gram-neg­a­tive bac­te­ria. Lead can­di­date, AAI101, is a be­ta-lac­ta­mase in­hibi­tor in... [more in­for­ma­tion]
Amarin Corporation [AMRN] US$1,075 MM MCap
Fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of ther­a­peu­tics to im­prove car­dio­vas­cu­lar health. Vas­ce­pa is the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in... [more in­for­ma­tion]
Amphivena Therapeutics, Inc.
Am­phive­na Ther­a­peu­tics, found­ed in 2013, is a pri­vate biotech­nol­o­gy com­pany de­vel­op­ing AMV654, a CD33/CD3-bis­pe­cif­ic T cell en­gag­ing anti­body for the treat­ment of AML and MDS. MPM Cap­i­tal,... [more in­for­ma­tion]
Anavex Life Sciences Corp. [AVXL] US$133 MM MCap
Ex­pects to ad­vance ANAVEX 2-73 in 4Q 2017 in­to a Phase II/III trial for the treat­ment of Alzheimer’s dis­ease; ANAVEX 2-73 al­so re­ceived or­phan drug desig­na­tion from the FDA in Rett Syn­drome. MOA:... [more in­for­ma­tion]
AngioGenex [AGGX] US$5 MM MCap
From MSKCC & Johns Hop­kins. De­vel­op­ing a small molecule, first-in-class Id-tar­get­ed an­ta­g­on­ist. Id is well-pub­lished, pre­vi­ous­ly "un­hit" tar­get. In­hibi­tor of Dif­fer­en­ti­a­tion (Id) pro­tein is sole­ly... [more in­for­ma­tion]
Apricus Biosciences, Inc. [APRI] US$40 MM MCap
Ad­vanc­ing medicines in urol­o­gy and rheu­ma­tol­o­gy, with two prod­uct can­di­dates in de­vel­op­ment. Fo­cused on U.S. ap­pro­val of Vi­taros, a top­i­cal gel for erec­tile dys­func­tion; NDA re-sub­mitt­ed in Q3 2017... [more in­for­ma­tion]
Aptamir, Inc.
[more in­for­ma­tion]
Aquinox Pharmaceuticals, Inc. [AQXP] US$276 MM MCap
Dis­cov­er­ing and de­vel­op­ing tar­get­ed ther­a­peu­tics in in­flam­ma­tion and im­muno-on­col­o­gy. Lead as­set, AQX-1125, is an oral, once dai­ly, small molecule ac­ti­va­tor of SHIP1. AQX-1125 is cur­rent­ly in Ph3 for... [more in­for­ma­tion]
A pri­vate, clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany that has lev­er­aged its plat­form of benz­imi­da­zole deri­va­tives to de­vel­op a ro­bust drug pipe­line of oral­ly avai­l­able, po­tent, and se­lec­tive small... [more in­for­ma­tion]
Ascentage Pharma
Glob­al­ly-fo­cused clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing first- and best-in-class tar­get­ed ther­a­peu­tics for can­cers, he­p­ati­tis B & age-re­lat­ed dis­eas­es. As­cen­t­age is a lead­er in the de­sign... [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung... [more in­for­ma­tion]
Aurinia Pharmaceuticals, Inc. [AUPH] US$468 MM MCap
A late stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of its nov­el ther­a­peu­tic im­muno­mo­d­u­lat­ing drug can­di­date, vo­clos­porin, for the treat­ment of lu­pus nephri­tis. Our strat­e­gy is to... [more in­for­ma­tion]
AxoGen [AXGN] US$963 MM MCap
Rev­enue gen­er­at­ing, ded­i­cat­ed to pe­ripher­al nerve re­pair with a port­fo­lio of re­gen­er­a­tive medicine prod­ucts avai­l­able in the US, Ca­na­da and sev­er­al other coun­tries. Prod­ucts in­clude Avance Nerve... [more in­for­ma­tion]
Bavarian Nordic A/S [BVNRY] US$1,214 MM MCap
Vaccines for in­fec­tious dis­eas­es and on­col­o­gy. Can­cer vaccines in com­bo with mul­ti­ple check­point in­hibi­tors (Roche/Mer­ck/BMS). Uni­ver­sal RSV vaccine with pos­i­tive phase 2 da­ta. Re­cent con­tract from US... [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$259 MM MCap
De­vel­op­ing CAR T/TCR ther­a­pies with molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­abling phar­ma­co­log­ic con­trol over cells for en­hanced safe­ty and ef­fi­ca­cy. Mul­ti­ple Ph 1/2 trials are un­der­way:... [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$1,125 MM MCap
De­vel­op­ing a port­fo­lio of in­no­va­tive, late-stage prod­uct can­di­dates tar­get­ing neu­ro­log­i­cal dis­eas­es, in­clud­ing rare di­s­or­ders. Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP... [more in­for­ma­tion]
BioPharmX [BPMX] US$16 MM MCap
Der­ma­tol­o­gy-fo­cused, de­vel­op­ing BPX-01 for top­i­cal mino­cy­c­line acne and rosacea treat­ment, based on its nov­el hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. Re­port­ed Ph IIb da­ta with BPX-01 in acne. [more in­for­ma­tion]
Bonesupport AB [STO-BONEX]
Or­tho­bi­o­log­ics com­pany that de­vel­ops and mar­kets CE­R­A­MENT®, an in­no­va­tive range of ra­dio­paque in­jectable os­teo­con­duc­tive and drug-elut­ing bio­ce­ram­ic prod­ucts that have a proven abil­i­ty to heal... [more in­for­ma­tion]
Ca­lyxt is an Ag­biotech com­pany fo­cused on de­vel­op­ing crops with healthi­er char­ac­teris­tics. Cap­i­tal­iz­ing on its team and new tech­nolo­gies, the com­pany’s mis­sion is to de­vel­op a nov­el gen­er­a­tion of... [more in­for­ma­tion]
Camurus AB [CAMX:ST] SKr5,294 MM MCap
Com­bines pro­pri­e­tary Fluid­Crys­tal® for­mu­la­tion for sol­u­bi­l­iza­tion and sta­bi­l­iza­tion with ac­tive phar­ma­ceu­ti­cal sub­s­tances. Lead prod­uct is CAM2038, for Opi­oid de­pen­dence. Phase III read­out showed... [more in­for­ma­tion]
Catabasis Pharmaceuticals Inc [CATB] US$35 MM MCap
Rare dis­ease pipe­line, with lead prod­uct Edasa­lonex­ent pre­par­ing for Ph 3 trial in Duchenne mus­cu­lar dys­tro­phy re­gard­less of mu­ta­tion type. Start Ph 3 trial in H1 2018 with North Star Am­bu­la­to­ry... [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$384 MM MCap
De­vel­op­ing Fir­dapse for the treat­ment of or­phan dis­ease in­di­ca­tion, Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) with pos­i­tive Ph 3 da­ta and ad­di­tio­n­al Ph 3 trial re­sults ex­pect­ed in 2017. Mul­ti­ple... [more in­for­ma­tion]
Cellectis SA [CLLS] US$1,059 MM MCap
Lead­er in en­gi­neered al­lo­gene­ic (off-the-shelf) CAR-T ther­a­peu­tics. Pipe­line in­cludes pro­pri­e­tary pro­grams and Pfiz­er and Servi­er part­n­er­ships on nu­mer­ous tar­gets in on­col­o­gy. Lead in­ter­nal pro­gram... [more in­for­ma­tion]
Chi-Med [HCM] US$5,256 MM MCap
De­vel­op­ment pipe­line of eight nov­el late stage on­col­o­gy can­di­dates, with five Ph 3 trials un­der­way, fu­eled by its pro­f­itable Chi­nese com­mer­cial plat­form. Fruquin­tinib (VEG­FR in­hibi­tor, LLY-part­nered)... [more in­for­ma­tion]
A com­mer­cial stage, pre­ci­sion gene edit­ing com­pany. Cibus' tech­nol­o­gy has ap­pli­ca­tions in non-GMO crop de­vel­op­ment, in­dus­trial biotech and hu­man health. The com­pany uti­l­izes Gene Re­pair... [more in­for­ma­tion]
CTI BioPharma [CTIC] US$150 MM MCap
New ma­n­age­ment team, clin­i­cal di­rec­tion, and fi­nanc­ing led by Or­biMed and BVF in mid-2017. - pa­cri­tinib (JAK2 in­hibi­tor) for the treat­ment of myelo­fi­bro­sis in Ph2 ba­cri­tinib fail­ures study with... [more in­for­ma­tion]
CureVac AG
One of the big 3 mR­NA com­pa­nies (Ger­many-based). MOA: Se­quence-op­ti­mized, un­mod­i­fied mR­NA. In­tra­tu­mo­ral ther­a­py Ph1 trial (mul­ti­ple on­col­o­gy in­di­ca­tions) ini­ti­at­ed Q4 2017. Pro­phy­lac­tic vaccine... [more in­for­ma­tion]
CytomX Therapeutics, Inc. [CTMX] US$981 MM MCap
Anti­body pro­drug (Pro­body) plat­form. Pro­body ther­a­peu­tics with pro­tease-cleav­able masks are de­signed to se­lec­tive­ly bind within the tu­mor mi­croen­vi­ron­ment. Cy­tomX is cur­rent­ly de­vel­op­ing part­nered and... [more in­for­ma­tion]
DBV Technologies SA Sponsored ADR [DBVT] US$1,252 MM MCap
De­vel­op­ing Vi­askin, a pro­pri­e­tary tech­nol­o­gy plat­form with broad po­ten­tial ap­pli­ca­tions in im­munother­a­py. Vi­askin is based on epi­cu­ta­neous im­munother­a­py, or EPIT, DBV’s pro­pri­e­tary method of... [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$374 MM MCap
De­vel­op re­search tools, di­ag­nos­tics and ther­a­peu­tics and pro­vides ref­er­ence lab­o­ra­to­ry ser­vices to the med­i­cal com­mu­ni­ty. Ac­tiv­i­ties in­clude R&D, man­u­fac­tur­ing and mar­ket­ing of biomed­i­cal re­search... [more in­for­ma­tion]
Epigenomics AG [EPGNY] US$131 MM MCap
Molec­u­lar di­ag­nos­tics com­pany fo­cused on non-in­va­sive screen­ing tests for on­col­o­gy. Lead prod­uct, Epi pro­Colon, is the first and on­ly FDA ap­proved blood based test to screen for colon can­cer. It is... [more in­for­ma­tion]
Erytech Pharma SA [ERYP] US$395 MM MCap
Ery­tech is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing ther­a­pies for rare forms of can­cer and or­phan dis­eas­es. [more in­for­ma­tion]
FivePrime Therapeutics [FPRX] US$635 MM MCap
Five Prime Ther­a­peu­tics, Inc. dis­cov­ers and de­vel­ops in­no­va­tive ther­a­peu­tics to im­prove the lives of pa­tients with se­ri­ous dis­eas­es. Five Prime's com­pre­hen­sive dis­cov­ery plat­form, which en­com­pass­es... [more in­for­ma­tion]
Flex Pharma, Inc. [FLKS] US$69 MM MCap
Ph 2 trials on­go­ing in ALS and Char­cot-Marie-Tooth with da­ta ex­pect­ed in ear­ly 2018. Ex­plo­ra­to­ry study in MS Spas­tic­i­ty. Safe­ty and tol­er­a­bil­i­ty as­sessed in 200+ sub­jects. MoA is based up­on nov­el... [more in­for­ma­tion]
Forward Pharma A/S [FWP] US$206 MM MCap
IP-gat­ed ac­cess to fu­ture roy­al­ties on lead­ing MS drug Tec­fidera® in US and EU de­pen­dent on up­com­ing le­gal de­ci­sions ex­pect­ed in 2018. [more in­for­ma­tion]
Genfit SA [GNFTF] US$954 MM MCap
Lead pro­gram Ela­fi­branor (GFT505) in Phase 3 trials for NASH. Ela­fi­branor is a PPAR al­pha/del­ta ag­on­ist cur­rent­ly in a Ph 3 trial with com­ple­tion of en­roll­ment for in­ter­im look ex­pect­ed 1Q18. On­go­ing... [more in­for­ma­tion]
GenSight Biologics [SIGHT.PA]
Gene ther­a­pies for se­vere reti­nal and CNS de­gen­er­a­tive patholo­gies. Lead prod­uct, GS010, is in Ph3 for the treat­ment of Le­ber Hered­i­tary Op­tic Neu­ro­pa­thy (LHON) with da­ta ex­pect­ed in 2018. Pipe­line... [more in­for­ma­tion]
Geron Corporation [GERN] US$306 MM MCap
-Ime­tel­s­tat is be­ing eval­u­at­ed in an on­go­ing Phase II trial (IM­bark) in re­lapsed/re­frac­to­ry MF, and a Phase II/III trial (IMerge) in low­er risk MDS. -GERN has part­nered with Janssen Biotech, Inc. to... [more in­for­ma­tion]
PankoMab-GEX™ in Ph 2b in TA-MUC1 pos­i­tive ovarian can­cer – ADC TA-MUC1 part­nered with Daiichi Sankyo. Us­ing Gly­co­Ex­press™ (GEX™) and Gly­co­Body™ (GET™) tech­nol­o­gy plat­forms. 6 I-O prod­ucts... [more in­for­ma­tion]
GW Pharmaceuticals PLC [GWPH] US$3,359 MM MCap
GW is a bio­phar­ma­ceu­ti­cal com­pany fo­cused on dis­cov­er­ing, de­vel­op­ing and com­mer­cial­iz­ing nov­el ther­a­peu­tics from its pro­pri­e­tary cann­abi­noid prod­uct plat­form in a broad range of dis­ease ar­eas. GW,... [more in­for­ma­tion]
Immunomedics, Inc. [IMMU] US$2,569 MM MCap
Im­munomedics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing mon­o­clo­n­al anti­body-based prod­ucts for the tar­get­ed treat­ment of can­cer, au­toim­mune di­s­or­ders and other se­ri­ous dis­eas­es. [more in­for­ma­tion]
Immutep (formerly Prima BioMed) [IMMP] US$44 MM MCap
Mar­ket lead­er de­vel­op­ing LAG-3 in im­muno-on­col­o­gy. Cur­rent trials: IM­P321 Ph2b (AI­PAC), po­ten­tial­ly EU-reg­is­tra­tio­n­al, for me­tastat­ic breast can­cer, top line da­ta 1H 2019; and IM­P321 Ph1 (TAC­TI-mel)... [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
(Pri­vate­ly held) Mor­phaBond ER™ US com­mer­cial launch Nov 2017 (FDA-ap­proved, first sin­gle-en­ti­ty abuse de­ter­rent ER mor­phine prod­uct) and Rox­y­Bond™ (FDA ap­proved, first and on­ly IR abuse-de­ter­rent... [more in­for­ma­tion]
Loxo Oncology, Inc. [LOXO] US$2,899 MM MCap
De­vel­ops tar­get­ed drugs for the treat­ment of can­cer in ge­net­i­cal­ly defined pa­tient pop­u­la­tions. Lead pro­gram: pur­pose built pan TRK in­hibi­tor in a Ph 2 solid tu­mor study with FDA break­through... [more in­for­ma­tion]
Medigene AG [MDGEF] US$347 MM MCap
Im­muno-on­col­o­gy com­pany fo­cused on per­so­n­al­ized T cell-based ther­a­pies. MDG1011, TCR tar­get­ing PRAME anti­gen, to en­ter clin­ic im­mi­nent­ly for bas­ket of he­ma­to­log­i­cal in­di­ca­tions (AML, MDS and MM). [more in­for­ma­tion]
Pro­f­itable clin­i­cal stage plat­form tech­nol­o­gy drug de­liv­ery com­pany fo­cused on long-act­ing in­jectable for­mu­la­tions for sub­cu­ta­neous de­liv­ery in­jec­tion to pro­vide sys­temic ef­fect while min­i­miz­ing... [more in­for­ma­tion]
Medivir AB [MVIR.B:ST] SKr900 MM MCap
Broad pipe­line of clin­i­cal stage as­sets in­clud­ing remeti­no­s­tat, a Ph 3 ready top­i­cal HDAC in­hibi­tor for the treat­ment of ear­ly-stage cu­ta­neous T-cell lym­pho­ma (CT­CL). Re­cent­ly an­nounced to­p­line da­ta... [more in­for­ma­tion]
MEI Pharma, Inc. [MEIP] US$81 MM MCap
Clin­i­cal on­col­o­gy com­pany fo­cused on the de­vel­op­ment of nov­el small molecules for the treat­ment of can­cer. Lead prod­uct Pra­ci­no­s­tat is a late clin­i­cal stage oral HDAC for the treat­ment of AML and MDS. [more in­for­ma­tion]
Meves Pharmaceuticals, Inc.
Meves Phar­ma­ceu­ti­cals, Inc. is de­vel­op­ing nu­cle­o­side based ther­a­pies for mi­to­chon­drial DNA (mtD­NA) de­ple­tion syn­dromes (MDS or MDDS), a cat­e­go­ry of se­vere ge­net­ic dis­eas­es. The ini­tial fo­cus is on... [more in­for­ma­tion]
MorphoSys AG [MPSYF] US$3,056 MM MCap
Clin­i­cal stage anti­body co. with dense pipe­line of >100 prod­ucts in mul­ti­ple stages/in­di­ca­tions. First part­n­er prod­uct on mar­ket (JNJ; Trem­fya for mod­er­ate to se­vere pso­ri­a­sis). Pro­pri­e­tary pro­gram... [more in­for­ma­tion]
Motif Bio plc [MTFB] US$149 MM MCap
Antibi­ot­ic com­pany (pos­i­tive Phase III da­ta an­nounced; NDA fil­ing ex­pect­ed 1Q 2018) fo­cused on life-threat­en­ing in­fec­tions caused by mul­ti-drug re­sis­tant bac­te­ria. To­p­line re­sults with Iclaprim in... [more in­for­ma­tion]
Naia Pharma
De­vel­op­ing a long-act­ing GLP-1 ag­on­ist ( XTEN™-GLP-1) for Short Bow­el Syn­drome, which has or­phan drug sta­tus. Ex­pects to ini­ti­ate re­cruit­ment the P1b study in 1H17, and file an NDA by the fourth... [more in­for­ma­tion]
Nanobiotix SA [NANO.PA]
De­vel­op­ing first in class nano­par­ti­cle-based ra­dio-en­hancer NBTXR3 for soft tis­sue sar­co­ma, head and neck, liv­er, pros­tate, rec­tal and other can­cers. Al­so be­ing de­vel­oped for in si­tu vac­ci­na­tion in... [more in­for­ma­tion]
NeuroRx [Private]
NRX-101 (Cy­clu­rad) in Ph 3 de­vel­op­ment (Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion with Acute Sui­ci­dal Idea­tion; plans to have da­ta by year-end 2018. MOA: tar­gets the NM­DA and 5-HT2a... [more in­for­ma­tion]
NexImmune, Inc.
Pri­vate IO com­pany de­vel­op­ing a unique ap­proach to anti­gen-spe­cif­ic T cell ther­a­py. Tech­nol­o­gy us­es syn­thet­ic nano­par­ti­cles de­c­o­rat­ed with a com­bi­na­tion of mul­ti­ple tu­mor rel­e­vant anti­gens and... [more in­for­ma­tion]
Nordic Nanovector ASA [NANO.OL]
Fo­cused on de­vel­op­ment of Anti­body-Ra­dionu­clide-Con­ju­gates (ARC). Lead as­set Be­ta­lutin, a nov­el an­ti-CD37 ARC (Luteti­um-177) ra­dioim­munother­a­peu­tic for the treat­ment of Non-Hodgkin Lym­pho­ma, en­ter­ing... [more in­for­ma­tion]
Novus Therapeutics [NVUS] US$27 MM MCap
Novus Ther­a­peu­tics is a de­vel­op­ment stage phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of prod­ucts for di­s­or­ders of the ear, nose, and throat (ENT). Novus has two tech­nolo­gies, each of which has... [more in­for­ma­tion]
OncoMed Pharmaceuticals [OMED] US$109 MM MCap
Cel­gene part­n­er­ship with near-term po­ten­tial mile­s­tones of $98M for an­ti-TIG­IT, ros­man­tuzumab (RSPO3 fu­sions) and navi­cix­izumab (an­ti-DL­L4/VEGF bis­pe­cif­ic) a clin­i­cal-stage com­pany dis­cov­er­ing and... [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr3,336 MM MCap
De­vel­op­ing Yga­lo (melflufen), a next gen­er­a­tion alky­la­tor that pref­er­en­tial­ly tar­gets can­cer cells via pep­ti­dase tar­get­ing, for mul­ti­ple myelo­ma. Yga­lo over­comes re­sis­tance mech­anisms that im­pact... [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
De­vel­op­ing treat­ments for the un­der­ly­ing caus­es of can­cer and CNS dis­eas­es by tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, al­so known as KD­M1A), a hi­s­tone mod­i­fy­ing en­zyme. Lead on­col­o­gy com­pound,... [more in­for­ma­tion]
Fo­cused on anes­th­e­sia around game chang­ing as­set Remi­ma­zo­lam, a short-act­ing anes­thet­ic. Remi­ma­zo­lam com­plet­ed a pos­i­tive Ph 3 in pro­ce­du­ral se­da­tion in the US. Pos­i­tive safe­ty da­ta in ASA III/IV... [more in­for­ma­tion]
PharmaMar SA [PHM:MA]
1H 2017 to­tal rev­enues of &eu­ro;96.9M. Yon­delis for soft tis­sue sar­co­ma and ovarian can­cer is com­mer­cial­ized with a di­rect sales-force in Eu­rope and part­n­er­ship in US with Janssen. Zep­syre cur­rent­ly in... [more in­for­ma­tion]
Pharming Group NV [PHARM.AS]
Lead RU­CON­EST is an rhC1-es­terase in­hibi­tor mar­ket­ed to treat an­gioede­ma at­tacks in pa­tients with HAE with 100% re­sponse rate, no re­lapse, side ef­fects, or plas­ma risk. Com­plet­ed Ph II for pro­phy­laxis... [more in­for­ma­tion]
PhaseBio Pharmaceuticals, Inc.
Clin­i­cal-stage, de­vel­op­ing new and im­proved bio­ther­a­peu­tics for the treat­ment of or­phan dis­eas­es, with an ini­tial fo­cus on car­diopul­mo­nary di­s­or­ders. Pro­pri­e­tary tech­nol­o­gy plat­form us­es re­com­bi­nant... [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr578 MM MCap
Urol­o­gy-fo­cused spec-phar­ma. Hexvix®/Cysview® on mar­ket for the de­tec­tion and ma­n­age­ment of blad­der can­cer. Com­mer­cial­ized us­ing Co’s spe­cial­ist sales­force in Nordic and US; part­nered in other... [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$332 MM MCap
De­vel­op­ing an­ti­calins (re­com­bi­nant pro­teins dif­fer­en­ti­at­ed from MAbs) for can­cer, se­vere asth­ma and ane­mia. PRS-060 As­traZene­ca part­n­er pro­gram first sub­ject en­rolled in De­cem­ber 2017. Co-de­vel­op­ment... [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Third Rock Ven­tures found­ed and fund­ed com­pany har­ness­ing the ther­a­peu­tic po­ten­tial of in­te­grin bi­ol­o­gy and TGF-be­ta mo­d­u­la­tion. - Build­ing a pa­tient reg­istry for cer­tain ar­eas of fi­brot­ic dis­ease to... [more in­for­ma­tion]
Poxel SA [POXEL:PA] €156 MM MCap
De­vel­op­ing safer and more ef­fec­tive ther­a­pies for metabolic dis­eas­es. Imeglimin (a mi­to­chon­dria-based MOA) for Type 2 di­a­betes will be­gin Ph 3 in Ja­pan with Asian part­n­er Su­m­i­t­o­mo Dainip­pon in 4Q17. [more in­for­ma­tion]
Probiodrug AG [PRBGF] US$129 MM MCap
Pos­i­tive da­ta in June 2017 from Ph 2a (SAPHIR) clin­i­cal trial for PQ912, for Alzheimer’s Dis­ease (AD). MOA: first in class small molecule QC in­hibi­tor. Tar­gets a spe­cif­ic type of Abe­ta,... [more in­for­ma­tion]
ProQR Therapeutics NV [PRQR] US$76 MM MCap
Trans­for­ma­tive RNA medicines for the treat­ment of se­vere or­phan dis­eas­es such as CF and LCA Type 10, based on pro­pri­e­tary RNA re­pair plat­form tech­nolo­gies. Pro­QR's lead clin­i­cal pro­gram, QR-010, is in... [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$389 MM MCap
Pro­ta­g­on­ist uti­l­izes a pro­pri­e­tary pep­tide tech­nol­o­gy plat­form to de­vel­op first-in-class oral tar­get­ed ther­a­py-based drugs that work by block­ing bi­o­log­i­cal path­ways that are cur­rent­ly tar­get­ed by... [more in­for­ma­tion]
Protalix BioTherapeutics [PLX] US$102 MM MCap
Lead, Ph 3 as­set, PRX-102, a mod­i­fied ver­sion of the re­com­bi­nant hu­man al­pha-GAL-A pro­tein, for the treat­ment of Fab­ry dis­ease. Part­nered with Chiezi in EU brings in up-front+mile­s­tones. Other as­sets... [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$383 MM MCap
A de­vel­op­ment-stage med­i­cal de­vice com­pany us­ing a nov­el and pro­pri­e­tary plat­form tech­nol­o­gy called Nano-Pulse Elec­tro-Sig­nal­ing or NPES. NPES is a lo­cal and drug-free tech­nol­o­gy that uti­l­izes... [more in­for­ma­tion]
RedHill Biopharma [RDHL] US$111 MM MCap
Three com­pounds in Ph3 de­vel­op­ment, RHB-105 for H.Py­lori, RHB-104 for Crohn’s and BEKIN­DA for gas­troen­teri­tis and gas­tri­tis. Ad­di­tio­n­al as­sets in­clude YE­LI­VA, a SK2 se­lec­tive in­hibi­tor with a... [more in­for­ma­tion]
ReNeuron Group plc [RENE:LN] GBX45 MM MCap
Clin­i­cal-stage, UK-based cell ther­a­py com­pany with al­lo­gene­ic, off-the-shelf can­di­dates: chron­ic stroke dis­a­bil­i­ty (Ph3 trial de­sign ap­proved by FDA, ini­ti­a­tion ear­ly 2018); re­tini­tis pig­men­tosa... [more in­for­ma­tion]
Rigel Pharmaceuticals [RIGL] US$620 MM MCap
Rigel's lead prod­uct can­di­date is fos­ta­ma­tinib (Ta­valisse) for the treat­ment of chron­ic and per­sis­tent im­mune throm­bo­cy­tope­nia (ITP). On Oc­to­ber 2, 2017, the FDA in­di­cat­ed that it is not plan­n­ing to... [more in­for­ma­tion]
Savara Inc. [SVRA] US$397 MM MCap
De­vel­ops in­ha­la­tion ther­a­pies for the treat­ment of pa­tients with rare pul­mo­nary con­di­tions. Three pipe­line prod­ucts: Mol­gradex, an in­haled ne­b­u­l­ized GM-CSF to treat Pul­mo­nary Alve­o­lar Pro­tei­no­sis... [more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$343 MM MCap
Three clin­i­cal stage prod­uct can­di­dates. SL-401, an IL-3/CD123 tar­get­ed ther­a­py for BPD­CN, com­plet­ed re­cruit­ment of its piv­o­tal Ph 2 has Break­through Desig­na­tion for the treat­ment of pa­tients with... [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €813 MM MCap
Mar­ket lead­er in au­to­ma­tion sys­tems and soft­ware for the di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS... [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$344 MM MCap
Strong­bridge is a com­mer­cial-stage com­pany fo­cused on ther­a­pies for rare dis­eas­es. Launched KEVEYIS for pe­ri­od­ic par­tial paral­y­sis in April 2017 in the US. Lead clin­i­cal as­set RE­COR­LEV is in Phase 3... [more in­for­ma­tion]
Sutro Biopharma
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. The com­pany’s dis­cov­ery and de­vel­op­ment ef­forts are driv­en by... [more in­for­ma­tion]
Symic Bio
De­vel­op­ing a new ther­a­peu­tic cat­e­go­ry of bio­con­ju­gates that di­rect­ly tar­get the ex­tra­cel­lu­lar ma­trix (ECM). Two clin­i­cal Phase 1/2a can­di­dates which in­clude pre­ven­tion of pe­ripher­al vein graft fail­ure... [more in­for­ma­tion]
Taiwan Liposome Company (TLC) [4152-TW]
Li­po­some de­liv­ery plat­form com­pany fo­cused on pain ma­n­age­ment, oph­thal­mol­o­gy, and on­col­o­gy. Lead pro­grams in Ph 2 trials in­clude TL­C599 in knee OA pain, TL­C399 in oph­thal­mol­o­gy / mac­u­lar ede­ma, and... [more in­for­ma­tion]
Targovax [TRVX:OS] NKr979 MM MCap
2 com­ple­men­tary ap­proach­es: (1) pep­tide-based I-O plat­form for pa­tients with RAS-mu­tat­ed can­cers: Ph 1/2 and Ph 1b trials on­go­ing w/2 da­ta read­outs in 2018 and (2) virus-based I-O plat­form (en­gi­neered... [more in­for­ma­tion]
TCR2 Therapeutics
Pro­pri­e­tary TRuC™ plat­form based on T cell re­cep­tor fu­sion con­structs that em­ploy the full sig­nal­ing pow­er of the T cell re­cep­tor (TCR). This cell ther­a­py ap­proach al­lows per­sis­tent killing of solid... [more in­for­ma­tion]
Tessa Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the treat­ment of can­cer by redi­rect­ing the body’s po­tent an­ti-vi­ral im­mune re­sponse to rec­og­nize and kill can­cer cells. Tes­sa’s core... [more in­for­ma­tion]
The Jackson Laboratory
Jack­son Labs (Pri­vate): Non-for pro­f­it re­search in ge­net­ic medicine has spear­head­ed dis­cov­ery in a va­ri­e­ty of dis­ease cat­e­gories in­clud­ing: on­col­o­gy, cen­tral ner­vous sys­tem dis­eas­es, mi­cro­biome... [more in­for­ma­tion]
TiGenix NV [TIG] US$231,187 MM MCap
Al­lo­gene­ic stem cells. Lead prod­uct, Cx601 for the treat­ment of com­plex pe­ria­nal fis­tu­las, has been filed for reg­u­la­to­ry ap­pro­val in Eu­rope and will com­mence a glob­al Phase III trial in the U.S. [more in­for­ma­tion]
Tocagen Inc. [TOCA] US$280 MM MCap
Can­cer-se­lec­tive gene ther­a­py com­pany. Lead pro­gram To­ca 511 and To­ca FC are be­ing studied in a reg­is­tra­tio­n­al Ph 2/3 trial for re­cur­rent high grade glio­ma (rHGG). A Ph 1 study of To­ca 511 and To­ca FC... [more in­for­ma­tion]
TXP Pharma
Lead pro­gram TXP-1214 is a Ph 2b/3 ready me­lano­cortin re­cep­tor (MCR) ag­on­ist for Acute Kid­ney In­jury (AKI) in pa­tients un­der­go­ing open ch­est car­di­ac surgery, plus MS. MOA: tar­get­ing the me­lano­cortin... [more in­for­ma­tion]
Vericel Corporation [VCEL] US$234 MM MCap
Au­tol­o­gous cell ther­a­py com­pany, mar­ket­ing au­tol­o­gous cell ther­a­py prod­ucts in the US. Com­menced MA­CI launch ac­tiv­i­ties and an­nounced treat­ment of the first pa­tient on Feb 1, 2017. Al­so mar­kets... [more in­for­ma­tion]
Veru Healthcare [VERU] US$72 MM MCap
De­vel­op­ing and com­mer­cial­iz­ing phar­ma­ceu­ti­cals and de­vices in urol­o­gy and on­col­o­gy. Uti­l­izes the 505(b)(2) path­way for more eco­nom­i­cal and fast-track ap­pro­val pro­cess­es. Prod­uct can­di­dates are for... [more in­for­ma­tion]
Vital Therapies, Inc. [VTL] US$232 MM MCap
Vi­tal Ther­a­pies, Inc. is a bio­ther­a­peu­tic com­pany de­vel­op­ing a cell-based ther­a­py tar­get­ing the treat­ment of acute forms of liv­er fail­ure. The Com­pany's ELAD Sys­tem is an ex­tra­cor­po­re­al hu­man... [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$187 MM MCap
Late-stage, Ph. 3 Alzheimer's da­ta read-out ear­ly 2018. Azeli­ra­gon - oral, small-molecule in­hibi­tor of the Re­cep­tor for Ad­vanced Gly­ca­tion End­prod­ucts (RAGE), lies up­stream to AD patholo­gies like... [more in­for­ma­tion]
Wave Life Sciences Ltd. [WVE] US$1,056 MM MCap
Wave is a clin­i­cal stage biotech com­pany fo­cused on de­liv­er­ing trans­for­ma­tio­n­al ther­a­pies for pa­tients with se­ri­ous, ge­net­i­cal­ly-defined dis­eas­es. Its chem­istry plat­form en­ables the cre­a­tion of high­ly... [more in­for­ma­tion]
Wilson Therapeutics [WTX:ST] SKr3,752 MM MCap
Fo­cused on rare dis­eas­es. Ex­pects to ad­vance WTX101, a nov­el first-in-class cop­per-pro­tein-bind­ing agent for treat­ment of Wil­son Dis­ease in­to piv­o­tal Phase 3 FO­CuS study in ear­ly 2018; grant­ed OD in... [more in­for­ma­tion]
XBrane Biopharma AB [XBRANE:ST] SKr477 MM MCap
Xbrane is a bio­phar­ma­ceu­ti­cal com­pany spe­cial­ized in high de­mand biosim­i­lars and long act­ing in­jecta­bles. The seg­ment has a high en­try bar­ri­er, driv­en by high pro­duc­tion com­plex­i­ty and the need of... [more in­for­ma­tion]
ZAI Laboratory [ZLAB] US$1,116 MM MCap
Zai Lab is a Shang­hai-based in­no­va­tive bio­phar­ma­ceu­ti­cal com­pany fo­cused on bring­ing trans­for­ma­tive medicines for can­cer, au­toim­mune and in­fec­tious dis­eas­es to pa­tients in Chi­na and around the world. [more in­for­ma­tion]